The role of strain variation in BAX and BCL-2 expression in murine bleomycin-induced pulmonary fibrosis

Pakistan Journal of Biological Sciences

Volumn 11, Issue 23, 2008, Pages 2606-2612

  Safaeian, Leila ^a   Jafarian, A ^a   Rabbani, M ^a   Sadeghi, H M ^a   Torabinia, N ^a   Alavi, S A ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Isfahan Science and Technology Town (ISTT)   (Iran)

Author keywords

BAX; BCL 2; Bleomycin; Mice; Pulmonary fibrosis

Indexed keywords

MURINAE; MUS;

BLEOMYCIN; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL; ARTICLE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; METABOLISM; MOUSE; MOUSE STRAIN; PATHOLOGY; SPECIES DIFFERENCE;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BLEOMYCIN; GENE EXPRESSION REGULATION; GENETIC VARIATION; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PULMONARY FIBROSIS; SPECIES SPECIFICITY;

EID: 68349159286     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2008.2606.2612     Document Type: Article

References (30)

1. Adams, J.M. and S. Cory, 1998. The BCL-2 protein family: Arbiters of cell survival. Science, 281: 1322-1326.
2. Baecher-Allan, C.M. and R.K. Barth, 1993. PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Reg. Immunol., 5: 207-217.
3. Bonniaud, P., G. Martin, P.J. Margetts, K. Ask and J. Robertson et al., 2004. Connective tissue growth factor is crucial to inducing a profibrotic environment in fibrosis-resistant BALB/c mouse lungs. Am. J. Respir. Cell. Mol. Biol., 31: 510-516.
4. Budinger, G.R., G.M. Mutlu, J. Eisenbart, A.C. Fuller and A.A. Bellmeyer et al., 2006. Proapoptotic Bid is required for pulmonary fibrosis. Proc. Natl. Acad. Sci. USA., 21: 4604-4609.
5. Giorno, R., 1984. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn. Immunol., 2: 161-166.
6. Guinee, D., E. Jr. Brambilla, M. Fleming, T. Hayashi and M. Rahn et al., 1997. The potential role of BAX and BCL-2 expression in diffuse alveolar damage. Am. J. Pathol., 151: 999-1007.
7. Hagimoto, N., K. Kuwano, Y. Nomoto, R. Kunitake and N. Hara, 1997. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell. Mol. Biol., 16: 91-101.
8. Harrison, J.H. and J.S. Lazo, 1988. Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther., 247: 1052-1058.
9. Hoshino, T., H. Nakamura, M. Okamoto, S. Kato and S. Araya et al., 2003. Redox-active protein thioredoxin prevents proinflammatory cytokine-or bleomycin-induced lung injury. Am. J. Respir. Crit. Care Med., 168: 1075-1083.
10. Hoyt, D.J. and J.S. Lazo, 1992. Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitroexposure of lung slices to bleomycin. Am. J. Respir. Cell. Mol. Biol., 7: 645-651.
11. Izbicki, G., M.J. Segel, T.G. Christensen, M.W. Conner and R. Breuer, 2002. Time course of bleomycin-induced lung fibrosis. Int. J. Exp. Pathol., 83: 111-119.
12. Kang, H.R., S.J. Cho, C.G. Lee, R.J. Homer and J.A. Elias, 2007. Transforming growth factor (TGF)-beta 1 stimulates pulmonary fibrosis and inflammation via a BAX-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J. Biol. Chem., 282: 7723-7732.
13. Kazufumi, M., N. Sonoko, K. Masanori, I. Takateru and O. Akira, 1997. Expression of BCL-2 protein and APO-1 (Fas antigen) in the lung tissue from patients with idiopathic pulmonary fibrosis. Microsc. Res. Technol., 38: 480-487.
14. Kinloch, R.A., J.M. Treherne, L.M. Furness and I. Hajimohamadreza, 1999. The pharmacology of apoptosis. Trends Pharmacol. Sci., 20: 35-42.
15. Korsmeyer, S.J., X.M. Yin, Z.N. Oltvai, D.J. Veis-Novack and G.P. Linette, 1995. Reactive oxygen species and the regulation of cell death by the BCL-2 gene family. Biochim. Biophys. Acta, 1271: 63-66.
16. Kuwano, K., N. Hagimoto and N. Hara, 2001. Molecular mechanisms of pulmonary fibrosis and current treatment. Curr. Mol. Med., 1: 551-573.
17. Kuwano, K., N. Hagimoto, T. Tanaka, M. Kawasaki and R. Kunitake et al., 2000. Expression of apoptosis-regulatory genes in epithelial cells in pulmonary fibrosis in mice. J. Pathol., 190: 221-229.
18. Lazo, J.S., D.G. Hoyt, S.M. Sebti and B.R. Pitt, 1990. Bleomycin: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol. Ther., 47: 347-358.
19. Lee, V.Y., C. Schroedl, J.K. Brunelle, L.J. Buccellato and O.I. Akinci et al., 2005. Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death. Am. J. Physiol. Lung. Cell. Mol. Physiol., 289: L521-528.
20. Leikauf, G.D., S.A. McDowell, C.J. Bachurski, B.J. Aronow and K. Gammon et al., 2001. Functional genomics of oxidant-induced lung injury. Adv. Exp. Med. Biol., 500: 479-487.
21. Lemay, A.M. and C.K. Haston, 2005. Bleomycin-induced pulmonary fibrosis susceptibility genes in AcB/BcA recombinant congenic mice. Physiol. Genomics, 23: 54-61.
22. Mason, R.J., M.I. Schwarz, G.W. Hunninghake and R.A. Musson, 1999. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present and future. Am. J. Respir. Crit. Care Med., 160: 1771-1777.
23. Mermigkis, C.M., K. Tsakanika, V. Polychronopoulos, N. Karagianidis and D. Mermigkis et al., 2001. Expression of BCL-2 protein in bronchoalveolar lavage cell populations from patients with idiopathic pulmonary fibrosis. Acta. Cytol., 45: 914-918.
24. Miyashita, T., S. Krajewski, M. Krajewska, H.G. Wang and H.K. Lin et al., 1994. Tumor suppressor p53 is a regulator of BCL-2 and BAX gene expression in vitro and in vivo. Oncogene, 9: 1799-1805.
25. Oltvai, Z.N., C.L. Milliman and S.J. Korsmeyer, 1993. BCL-2 heterodimerizes in vivo with a conserved homolog, BAX, that accelerates programmed cell death. Cell, 74: 609-619.
26. Plataki, M., A.V. Koutsopoulos, K. Darivianaki, G. Delides and N.M. Siafakas et al., 2005. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest, 127: 266-274.
27. Razzaque, M.S., N. Ahsan and T. Taguchi, 2002. Role of apoptosis in fibrogenesis. Nephron, 90: 365-372.
28. Selman, M., T.E. King and A. Pardo, 2001. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med., 134: 136-151.
29. Uhal, B.D., 2002. Apoptosis in lung fibrosis and repair. Chest, 122: 293S-298S.
30. Woessner, J.F., 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys., 93: 440-447.